It is the first study to analyse the molecular bases of comorbidity between Alzheimer’s disease and glioblastoma
Mitochondrial dysfunction plays a fundamental role in this relationship
Patients with Alzheimer’s disease have a higher risk of developing glioblastoma and a lower risk of lung cancer. A paper published in Scientific Reports by researchers from the Spanish National Cancer Research Centre (CNIO), headed by Alfonso Valencia, a researcher affiliated to the CNIO and to the Barcelona Supercomputing Centre (BSC), describes the biological processes that underlie this comorbidity.
The increase in life expectancy has resulted in many people developing multiple diseases. This phenomenon is known as comorbidity, and there may be a direct relationship, when in the presence of one pathology, there is a higher risk of another emerging; or an inverse relationship, having a certain condition implies a lower risk of developing another. Epidemiology has identified a number of relationships of this type, such as a lower incidence of cancer in people with certain diseases that affect the central nervous system.
A paper published in 2014 in the journal PLoS Genetics by researchers from the revealed that over-expressed genes in central nervous system diseases (Alzheimer’s disease, Parkinson’s disease and schizophrenia) were under-expressed in cancer (lung, colon, and prostate) and vice versa. Understanding the molecular bases of these processes provides important information regarding the study of the causes of each disease and the possible design of new therapeutic strategies (drug repositioning).
The paper published now in Scientific Reports delves into the relationship between Alzheimer’s disease and brain tumours (glioblastoma, in particular), using lung cancer data as reference and applying a new meta-analytical method explicitly developed for this case.
MITOCHONDRIAL ALTERATION AND CHRONIC INFLAMMATION
“The analysis of glioblastoma, which has a direct comorbidity link with Alzheimer’s and that, in addition, originates in the same organ, has allowed us to better understand the molecular comorbidity between Alzheimer’s disease and cancer, and eliminate tissue-dependent bias,” says Jon Sánchez-Valle, leading author of the paper.
The analyses conducted on more than 1000 samples from patients with these diseases have identified 198 genes whose function is altered significantly in the three cases. Of these, 112 had a similar pattern in Alzheimer’s disease and glioblastoma and the opposite pattern in lung cancer.
By comparing the biological processes altered through the deregulation of these genes, the authors confirmed that mitochondrial dysfunction plays a key role in the development of Alzheimer’s and could also lead to an increased risk of brain tumours in patients with Alzheimer’s disease, through the emergence of chronic inflammation in the brain. The decrease in the energy supply and the generation of reactive oxygen species (ROS) due to alterations in the mitochondrial function would, in turn, be related to the protection against lung cancer in patients with Alzheimer’s disease.
These results, the authors point out, could help in the search for new uses for existing drugs and new therapeutic combinations to treat these diseases based on patient-specific genomic information.
This research has been funded by the Spanish Ministry of Economy and Competitiveness (BIO2012-40205 and BFU2015-71241-R) and it was carried out in the framework of the Platform for Biomolecular and Bioinformatics Resource (PT13/0001/0030 of the ISCIII), which is funded through the European Regional Development Fund (ERDF). RT-S acknowledges funding from the Generalitat Valenciana (PROMETEOII/2015/021) and the national grant PI14/00894 from the Spanish “Plan Nacional de I + D + I 2013-2016,” co-funded by the “ISCIII Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER).
A molecular hypothesis to explain direct and inverse co-morbidities between Alzheimer’s Disease, Glioblastoma and Lung cancer. Jon Sánchez-Valle, Héctor Tejero, Kristina Ibáñez, José Luis Portero, Martin Krallinger, Fátima Al-Shahrour, Rafael Tabarés-Seisdedos, Anaïs Baudot & Alfonso Valencia (Scientific Reports 2017). DOI: 10.1038/s41598-017-04400-6
Centro Nacional de Investigaciones Oncológicas